---
schema_version: "secwatch.filing_event.v1"
accession: "0001731122-22-000700"
form_type: "8-K"
ticker: "AVXL"
cik: "0001314052"
company_name: "ANAVEX LIFE SCIENCES CORP."
filed_at: "2022-04-08T23:59:59+00:00"
generated_at: "2026-06-26T08:26:01.463028+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Anavex extends CEO Missling's contract through July 2025; grants 500K options tied to clinical milestones

## Summary
- CEO Christopher Missling's employment agreement extended to July 5, 2025.
- Base salary increased to $700,000 annually effective July 5, 2022, with target bonus of 20%.
- Grant of 500,000 options vesting upon completion of three clinical trial milestones (Alzheimer’s Phase 2b/3, Parkinson’s trial initiation, Fragile X Phase 2/3 initiation).
- Options exercise price equals closing price on grant date; accelerated vesting upon change in control.

## SEC filing metadata
- accession: 0001731122-22-000700
- form_type: 8-K
- ticker: AVXL
- cik: 0001314052
- company_name: ANAVEX LIFE SCIENCES CORP.
- filed_at: 2022-04-08T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1314052/000173112222000700/0001731122-22-000700-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1314052/000173112222000700/e3692_8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001731122-22-000700
- JSON: https://secwatch.observer/filing/0001731122-22-000700.json
- Plain text: https://secwatch.observer/filing/0001731122-22-000700.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.